Literature DB >> 31272327

Meta-Analysis of Accuracy of the Spot Sign for Predicting Hematoma Growth and Clinical Outcomes.

Thanh G Phan1,2, Natasha Krishnadas1,2, Vivian Wai Yun Lai1, Michael Batt1,2, Lee-Anne Slater3, Ronil V Chandra3, Velandai Srikanth4, Henry Ma1,2.   

Abstract

Background and Purpose- The computed tomography angiographic spot sign refers to contrast leakage within intracerebral hemorrhage (ICH). It has been proposed as a surrogate radiological marker for ICH growth. We conducted a meta-analysis to study the accuracy of the spot sign for predicting ICH growth and mortality. Methods- PubMed, Medline, conference proceedings, and article references in English up to June 2017 were searched for studies reporting "computed tomography angiography" and "spot sign" or "intracerebral hemorrhage" and "spot sign." Each study was ranked on 27 criteria resulting in a quality rating score. Bivariate random effect meta-analysis was used to calculate positive and negative likelihood ratios and area under summary receiver operating characteristics curve for ICH growth and mortality. Hematoma growth was defined using the change in ≥6 mL or ≥33% increase in volume. Results- There were 26 studies describing 5085 patients, including 15 studies not used in previous meta-analyses. Positive likelihood ratio and negative likelihood ratio for ICH growth were 4.85 (95% CI, 3.85-6.02; I2=76.1%) and 0.49 (95% CI, 0.40-0.58) and mortality were 4.65 (95% CI, 3.67-5.90) and 0.55 (95% CI, 0.40-0.69), respectively. For ICH growth, the pooled sensitivity was 0.57 (95% CI, 0.49-0.64) and pooled false positive rate was 0.12 (95% CI, 0.09-0.14). The post-test probability of ICH growth was 0.57. The area under the curve for ICH growth and mortality was 0.86 and 0.87 (CIs are not provided in bivariate method). Meta-regression showed sensitivity of the test to decline significantly with subsequent year of publication (β=-0.148; 95% CI, -0.295 to -0.001; P=0.05). Higher quality assessment is associated with lower false positive rate (β=-0.074; 95% CI, -0.126 to -0.022; P=0.006). Conclusions- The high area under the curve potentially suggests that the spot sign can predict hematoma growth and mortality. Caution is recommended in its application given the heterogeneity across studies, which is appropriate given the data.

Entities:  

Keywords:  cerebral hemorrhage; computed tomography angiography; hematoma; incidence; sensitivity and specificity

Year:  2019        PMID: 31272327     DOI: 10.1161/STROKEAHA.118.024347

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  4 in total

1.  Early spot sign is associated with functional outcomes in primary intracerebral hemorrhage survivors.

Authors:  Wen-Che Tseng; Yu-Fen Wang; Tyng-Guey Wang; Ming-Yen Hsiao
Journal:  BMC Neurol       Date:  2021-03-20       Impact factor: 2.474

2.  Dual-Energy CT Angiography Improves Accuracy of Spot Sign for Predicting Hematoma Expansion in Intracerebral Hemorrhage.

Authors:  Michaël T J Peeters; Kim J D de Kort; Rik Houben; Wouter J P Henneman; Robert J van Oostenbrugge; Julie Staals; Alida A Postma
Journal:  J Stroke       Date:  2021-01-31       Impact factor: 6.967

3.  Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomised placebo-controlled double-blind multicentre trial.

Authors:  Geoffrey A Donnan; Stephen M Davis; Nawaf Yassi; Henry Zhao; Leonid Churilov; Bruce C V Campbell; Teddy Wu; Henry Ma; Andrew Cheung; Timothy Kleinig; Helen Brown; Philip Choi; Jiann-Shing Jeng; Annemarei Ranta; Hao-Kuang Wang; Geoffrey C Cloud; Rohan Grimley; Darshan Shah; Neil Spratt; Der-Yang Cho; Karim Mahawish; Lauren Sanders; John Worthington; Ben Clissold; Atte Meretoja; Vignan Yogendrakumar; Mai Duy Ton; Duc Phuc Dang; Nguyen Thai My Phuong; Huy-Thang Nguyen; Chung Y Hsu; Gagan Sharma; Peter J Mitchell; Bernard Yan; Mark W Parsons; Christopher Levi
Journal:  Stroke Vasc Neurol       Date:  2021-11-30

4.  Tranexamic acid for acute intracerebral haemorrhage growth based on imaging assessment (TRAIGE): a multicentre, randomised, placebo-controlled trial.

Authors:  Liping Liu; Yongjun Wang; Jingyi Liu; Ximing Nie; Hongqiu Gu; Qi Zhou; Haixin Sun; Ying Tan; Dacheng Liu; Lina Zheng; Jiahui Zhao; Yan Wang; Yibin Cao; Haomeng Zhu; Yunpeng Zhang; Lijin Yi; Yuehua Pu; Miao Wen; Zhonghua Yang; Shengjun Sun; Wenzhi Wang; Xingquan Zhao
Journal:  Stroke Vasc Neurol       Date:  2021-04-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.